NEW YORK (GenomeWeb) – Epistem announced this week the completion of the management buyout of Genedrive following an undisclosed investment by Foresight Group. Epistem provides preclinical and clinical research services across specialist therapeutic areas, such as oncology, gastrointestinal diseases, and toxicity and inflammatory diseases. Foresight's investment will enable Epistem to expand its next-generation sequencing and laser-capture technologies, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.